UniSuper Management Pty Ltd Has $2.19 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

UniSuper Management Pty Ltd increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,428 shares of the medical equipment provider’s stock after purchasing an additional 5,671 shares during the period. UniSuper Management Pty Ltd’s holdings in Hologic were worth $2,194,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter valued at $26,000. Groupama Asset Managment grew its stake in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $61.32 on Monday. The company has a market cap of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $65.24 and its 200 day simple moving average is $73.24. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.